Loading stock data…
Immunome (IMNM)
$19.96+0.56 (+2.89%)
Market ClosedLast close Jun 26
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunome, Inc. in the Healthcare sector is trading at $19.96 with a market capitalization of $2.0B. Wall Street consensus targets $35.77 (13 analysts), implying a +79.2% move over the next 12 months. The stock is currently 28% below its 52-week high of $27.65, remaining 1.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +79.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $4.01M↑ | $2.93M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$59.33M↑ | -$72.86M↓ | -$60.14M↓ | -$46.48M↓ | -$44.64M |
| Net Income | -$53.84M↑ | -$69.90M↓ | -$57.46M↓ | -$43.40M↓ | -$41.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset compris...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.15%
Volume
Today's trading volume
4.33M
Recent News
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?
Immunome, Inc. recently reported detailed efficacy and safety results from its global Phase 3 RINGSIDE trial of varegacestat in progressing desmoid tumors, showing statistically significant benefits in progression-free survival and pain reduction, and has already submitted a New Drug Application to the US FDA with an EU filing planned. An interesting aspect for investors is that the progression-free survival benefit appeared consistent across multiple prespecified patient subgroups, hinting...
Barclays initiates oncology-focused biotechs with positive outlook
Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. During the first quarter, the U.S. equity market declined, with the S&P 500 Index falling by 4.33%. The fixed-income sector also saw a downturn; the Bloomberg U.S. Aggregate Bond Index fell […]
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
Immunome, Inc. (NASDAQ:IMNM) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On April 29, Immunome, Inc. (NASDAQ:IMNM) reported the filing of a new drug application with the US Food and Drug Administration for varegacestat to treat people with desmoid tumors. The company grounded the filing in Phase […]